Reports Search Total = 1027

Peripheral Vascular Devices Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
115 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 115 pages
  • Published: 23-07-2019

Market Overview

 

Peripheral arterial disease (PAD) is caused by a narrowing or blocking of the blood vessels due to a plaque build-up. This condition can lead to tissue death, heart stroke, aneurysms, or kidney diseases, if left untreated. According to the National Institute of Health, one in every 20 American, who is over the age of 50, has PAD. It has been affecting eight to 12 million people in the United States, especially those over 50 years. As the population is growing, the prevalence of the disease is increasing, which could grow from 9.6 million to reach 19 million overall, globally by 2050. With the aging of the global population, it seems likely that PAD will be increasingly common in the future. Hence, the statistics show that the number of PAD is increasing at a faster pace, which is ultimately driving the market of peripheral arterial disease. Other factors, such as the rising demand for minimally-invasive procedures, especially for peripheral arterial disease, lifestyle changes, increase in aging population, and technological advancements have broadened the range of the peripheral vascular devices.

 

 

Scope of the Report

 

Vascular devices can be referred to as a medical device utilized in the case of catheterization post a cardiovascular surgery for the closure and achieving hemostasis in the artery.

 

 

Key Market Trends

 

Atherectomy Devices are expected to dominate the overall market

 

The market on the basis of device type is segmented into peripheral vascular stents, peripheral transluminal angioplasty (PTA) balloon catheters, peripheral transluminal angioplasty (PTA) guidewires, atherectomy devices, chronic total occlusion (CTO) devices, aortic stents, synthetic surgical grafts, embolic protection devices, and inferior vena cava filters. The atherectomy devices segment is expected to dominate the overall market, owing to the increasing prevalence of atherosclerosis, rising obesity, lifestyle-related disorders, and hence, the growing adoption.

 

 

North America dominates the peripheral vascular devices market

 

North America dominated the peripheral vascular devices market in 2018 and is expected to grow in the future due to factors, such as the rising incidence of cardiovascular diseases, growing geriatric population, and the strong presence of industry players in the region. Europe holds the second largest position in the market, which is followed by the APAC region.

 

 

Competitive Landscape

 

The presence of the major market players, such as Abbott, Boston Scientific Corporation, Becton Dickinson and Company, Cook Group, Medtronic, and others is intensifying the market competition. The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the globe.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Minimally-Invasive Procedures, Especially for Peripheral Arterial Disease
4.2.2 Increase in incidence of Peripheral Arterial Disease (PAD)
4.2.3 Lifestyle Changes and Increase in Ageing Population
4.2.4 Technological Advancements have broadened the Range of Peripheral Vascular Devices
4.3 Market Restraints
4.3.1 Delay in Marketing Approval for Peripheral Vascular Devices due to Stringent Regulations
4.3.2 Lack of Proper Reimbursement Policies for Peripheral Vascular Devices
4.3.3 Highly-Fragmented Market Leading To Peripheral Vascular Devices Price Erosion
4.4 Porters Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Device Type
5.1.1 Peripheral Vascular Stents
5.1.2 Peripheral Transluminal Angioplasty (PTA) Balloon Catheters
5.1.3 Peripheral Transluminal Angioplasty (PTA) Guidewires
5.1.4 Atherectomy Devices
5.1.5 Chronic Total Occlusion (CTO) Devices
5.1.6 Aortic Stents
5.1.7 Synthetic Surgical Grafts
5.1.8 Embolic Protection Devices
5.1.9 Inferior Vena Cava Filters
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Boston Scientific Corporation
6.1.3 Becton, Dickinson and Company
6.1.4 Cook Group
6.1.5 Cordis Corporation
6.1.6 Edward Lifesciences
6.1.7 Medtronic PLC
6.1.8 Volcano Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

 

MARKET SEGMENTATION

By Device Type
Peripheral Vascular Stents
Peripheral Transluminal Angioplasty (PTA) Balloon Catheters
Peripheral Transluminal Angioplasty (PTA) Guidewires
Atherectomy Devices
Chronic Total Occlusion (CTO) Devices
Aortic Stents
Synthetic Surgical Grafts
Embolic Protection Devices
Inferior Vena Cava Filters

Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Ophthalmology Drug and Device Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
114 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 114 pages
  • Published: 23-07-2019

Market Overview

 

The ophthalmology drug and device market is expected to witness a CAGR of 5.3% during the forecast period. Certain factors that are driving the growth of the market include demographic shift, impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and rising geriatric population.

Cataract volume registered a rapid increase in recent years. The aging population is expected to burden all areas of health care, and ophthalmologists provide approximately 90% of their procedure-based services to seniors. In many countries, cataract surgery is the most frequent surgical procedure performed, and it offers significant improvements in the quality of life of the elderly population at low costs. An increase in the demand for ophthalmological devices projects the future cataract surgery needs that are vital for human health resources and hospitals, and for surgical center management and planning.

Other factors, such as the availability of new drugs and devices and the prevalence of eye disease, are also expected to drive the market over the forecast period.

Many regulations are imposed by agencies, such as the FDA, to ensure the safety and efficacy of products. Due to frequent occurrences of violations, tighter regulations were enforced on the label contents. The cost of complying with FDA guidelines is expected to drive many small pharmacies out of business or force them to consolidate. For example, these regulations impose a beyond-use date of only five days for bevacizumab and other biologics. However, it takes 14 days just to test the sterility of these drugs, which means that the regulations for compounded ophthalmology drugs besides bevacizumab, such as ophthalmology mitomycin, and triamcinolone acetonide plus moxifloxacin hydrochloride injection, will become much more expensive or even unavailable.

Additionally, increasing healthcare cost and economic slowdown in developed countries are also restraining the market’s growth.

 

Scope of the Report

 

Ophthalmology is a branch of medicine that deals with the anatomy, physiology, and diseases of the eye. Ophthalmologists, who are specialists in medical and surgical eye problems, perform operations on eyes. They are specially trained to provide the full spectrum of eye care, from prescribing glasses and contact lenses to complex and delicate eye surgery. The devices include glasses, lenses, diagnostics, lasers, solutions, and surgical instruments.

 

Key Market Trends

 

Cataract Surgery Devices are Expected to Hold a Significant Market Share in the Surgical Device Type

 

According to the Royal College of Ophthalmologists, the United Kingdom, around 330,000 cataract operations are performed each year in England alone. It has been estimated that 30% of people aged 65 years or more have a visually impairing cataract in one or both eyes. Some populations tend to have a much higher prevalence of cataracts. For instance, 77% of the British people, aged 42 years or older, originating from the Indian subcontinent have cataracts. There is a threefold variation in the number of people having cataract surgery across England, owing to differences in health commissioning policies.

Similarly, as stated by the American Academy of Ophthalmology, approximately 24.5 million people in the United States have cataracts, which is the leading cause of blindness in the United States. Cataract surgery remains the most effective way to help restore vision for these people with cataracts.

 

North America Dominates the Market and Expected to do the Same during the Forecast Period

 

Due to the presence of well-established healthcare facilities, the rise in geriatric population in the region, and certain other factors, North America dominates the ophthalmology drug and device market. Owing to the constant increase in the American elderly population, as well as a movement toward vision correction and its usage among key demographics, an absolute increase in usage rates for most types of eyewear was observed in the United States. Additionally, the government of Canada states that the average revenue of the small and medium-sized enterprises, primarily engaged in retailing and fitting prescription eyeglasses, was found to be USD 565.2 thousand, in 2016, whereas the profit was around 77-78%.

 

Competitive Landscape

 

The ophthalmology drug and device market, which is highly competitive, consists of a number of major players. Companies, such as Alcon Inc., Bausch & Lomb Inc., Johnson & Johnson, and Carl Zeiss Meditec AG, among others, hold substantial market shares in the ophthalmology drug and device market.

Recently, various developments have been taking place in the market. For instance, in November 2017, Bausch & Lomb got Vyzulta approved for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Moreover, in November 2017, Zeiss introduced the cloud-based cataract surgery planning platform, Veracity Surgical, and announced the integration with leading EMRs.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Demographic Shift and Impact of Prevalence of Eye Disease

4.2.2 Technological Advancements in the Field of Ophthalmology

4.2.3 Rising Geriatric Population

4.3 Market Restraints

4.3.1 Increasing Healthcare Costs

4.3.2 Economic Slowdown in Developed Markets

4.3.3 Strict FDA Guidelines for Drug Approval

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 Device

5.1.1 Surgical Device

5.1.1.1 Glaucoma Surgery Devices

5.1.1.2 Cataract Surgery Devices

5.1.1.3 Refractive Surgery Devices

5.1.1.4 Vitreoretinal Surgery Devices

5.1.1.5 Other Surgical Devices

5.1.2 Diagnostic and Monitoring Device

5.1.2.1 Fundus Cameras

5.1.2.2 Ophthalmoscopes

5.1.2.3 Retinoscopes

5.1.2.4 Keratometers

5.1.2.5 Wavefront Aberrometers

5.1.2.6 Tonometers

5.1.2.7 Ophthalmic Ultrasound Imaging Systems

5.1.2.8 Optical Coherence Tomography Scanners

5.1.2.9 Visual Field Analyzers

5.1.2.10 Slit Lamps

5.1.2.11 Other Diagnostic and Monitoring Devices

5.1.3 Vision Care

5.1.3.1 Spectacles

5.1.3.2 Contact Lens

5.2 Drug

5.2.1 Glaucoma Drugs

5.2.2 Retinal Disorder Drugs

5.2.3 Dry Eye Drugs

5.2.4 Allergic Conjunctivitis and Inflammation Drugs

5.2.5 Other Drugs

5.3 Geography

5.3.1 North America

5.3.1.1 US

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 UK

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Alcon Inc.

6.1.2 Bausch & Lomb Inc.

6.1.3 Carl Zeiss Meditec AG

6.1.4 Essilor International SA

6.1.5 Haag-Streit Group

6.1.6 Johnson & Johnson

6.1.7 Nidek Co. Ltd

6.1.8 Topcon Corporation

6.1.9 Ziemer Ophthalmic Systems AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

Device

Surgical Device

Glaucoma Surgery Devices

Cataract Surgery Devices

Refractive Surgery Devices

Vitreoretinal Surgery Devices

Other Surgical Devices

Diagnostic and Monitoring Device

Fundus Cameras

Ophthalmoscopes

Retinoscopes

Keratometers

Wavefront Aberrometers

Tonometers

Ophthalmic Ultrasound Imaging Systems

Optical Coherence Tomography Scanners

Visual Field Analyzers

Slit Lamps

Other Diagnostic and Monitoring Devices

Vision Care

Spectacles

Contact Lens

 

Drug

Glaucoma Drugs

Retinal Disorder Drugs

Dry Eye Drugs

Allergic Conjunctivitis and Inflammation Drugs

Other Drugs

 

Geography

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Ophthalmic Lasers Market – Growth, Trends, and Forecast (2019-2024)

Healthcare Published by: Mordor Intelligence Market: Global
114 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 114 pages
  • Published: 23-07-2019

Market Overview

 

The ophthalmic lasers market is expected to register a CAGR of 4.9%, over the forecast period. Factors that are responsible for the growth of this market include high prevalence of ophthalmic disorders, increasing initiatives to control visual impairment, and increasing regulatory approvals for ophthalmic lasers.

 

FDA is aware that there has been, and continues to be, a considerable amount of research activity in the ophthalmic lasers arena. Hence, several number of eye lasers are receiving regulatory approvals, which help in driving the ophthalmic lasers market. In 2016, the China Food and Drug Administration (China FDA) had granted regulatory approval for the Ellex Medical Lasers Limited’s complete portfolio of glaucoma, vitreous floaters, and secondary cataract treatment lasers (collectively referred to as the “YAG laser” portfolio) in the Chinese market. With the company’s proprietary YAG laser portfolio now available to all ophthalmologists in China, the approval by China FDA had directly increased the sales in China, in 2017. Therefore, it is marked as an important milestone to expand its presence in the fast-growing market of Asia. Thus, the increase in regulatory approvals helps in driving the growth of the ophthalmic lasers market.

 

Scope of the Report

 

The ophthalmic laser is a medical device, which is used to target ophthalmic cells, in order to operate the ophthalmic disorders. Ophthalmic lasers are used for treating a wide range of eye problems. It is used in a variety of ophthalmic disorder procedures that include cataract surgery, laser trabeculoplasty, retinal photocoagulation, and laser iridotomy. Significant accuracy, low-cost, safe procedure, and convenient ophthalmic tools have increased the demand for ophthalmic lasers in the market.

 

Key Market Trends

 

Refractive Error Corrections is Expected to Hold the Highest Revenue in the Application Segment

 

In the application segment of the ophthalmic lasers market, refractive error corrections are projected to have the largest revenue during the forecast period. This is majorly due to the factors, such as the escalating number of refractive error cases among, both, children and adult population. Furthermore, increase in the application of femtosecond lasers in refractive error surgeries is helping in the growth of this segment.

 

North America Dominates the Market and is Expected to do Same during the Forecast Period

 

Currently, North America dominates the market for ophthalmic lasers, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share, owing to the increasing incidence rates of ophthalmic problems and increasing healthcare expenditure in the country, as well as the development of sophisticated healthcare infrastructure in the country.

 

Competitive Landscape

 

The ophthalmic market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. With rising incience of ophthalmic cases and increasing geriatric population, few other smaller players are expceted to enter the market. Some of the major players of the market are Alcon Laboratories Inc. (Novartis AG), Johnson & Johnson Surgical Vision Inc., Bausch & Lomb Incorporated (Valeant Pharmaceuticals International Inc.), Ellex Medical Lasers Limited, and IRIDEX Corporation, among others.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 High Prevalence of Ophthalmic Disorders

4.2.2 Increasing Regulatory Approvals for Ophthalmic Lasers

4.2.3 Increasing Initiatives to Control Visual Impairments

4.3 Market Restraints

4.3.1 Huge Cost Associated with Ophthalmic Laser Therapies

4.3.2 Reduced Availability of Skilled Practitioners

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product

5.1.1 Diode Lasers

5.1.2 Femtosecond Lasers

5.1.3 Excimer Lasers

5.1.4 Nd:YAG Lasers

5.1.5 SLT Lasers

5.1.6 Other Products

5.2 By Application

5.2.1 Glaucoma

5.2.2 Cataract Removal

5.2.3 Refractive Error Corrections

5.2.4 Diabetic Retinopathy

5.2.5 Other Applications

5.3 By End User

5.3.1 Hospitals

5.3.2 Eye Clinics

5.3.3 Other End Users

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East & Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East & Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Alcon Laboratories Inc. (Novartis AG)

6.1.2 Johnson & Johnson Surgical Vision Inc.

6.1.3 Bausch & Lomb Incorporated (Valeant Pharmaceuticals International Inc.)

6.1.4 Ellex Medical Lasers Limited

6.1.5 IRIDEX Corporation

6.1.6 LIGHTMED

6.1.7 Quantel Medical

6.1.8 SCHWIND Eye-tech-solutions

6.1.9 Lumenis

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Product

Diode Lasers

Femtosecond Lasers

Excimer Lasers

Nd:YAG Lasers

SLT Lasers

Other Products

 

By Application

Glaucoma

Cataract Removal

Refractive Error Corrections

Diabetic Retinopathy

Other Applications

 

By End User

Hospitals

Eye Clinics

Other End Users

 

Geography

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Pet Food Market – Growth, Trends, and Forecast (2019 – 2024)

Animal Nutrition & Wellness Published by: Mordor Intelligence Market: Global
158 pages Published: 23-07-2019
  • Animal Nutrition & Wellness
  • Mordor Intelligence
  • Global
  • 158 pages
  • Published: 23-07-2019

Market Overview

 

The global pet food market (henceforth, referred to as the market studied) was valued at USD 87.08 billion in 2019 and it is expected to register a CAGR of 5.4% during the forecast period (2019-2024). In 2019, North America is the largest geographical segment of the market studied and accounted for a share of around 39.2% of the overall market.

 

– Pet food industry is one of those industries, which has been performing well, despite the economic downturn. The world’s largest pet food markets are in the United States, France, Japan, and Germany, accounting for over half of the sales in pet food.


– According to the Association for Pet Obesity Prevention (APOP), 52.6% of the dogs and 57.6% of the cats in the United States are overweight or obese. This trend of rising obesity among pets mirrors human obesity patterns. As a result, the major players in the pet food market have started to follow human health trends, with foods to support weight loss.


– The major constraint identified in the growth of the global pet food market is the issue with the regulatory system.


Scope of the Report

 

The pet food market is segmented by animal type (dogs, cats, birds, and other animal types), product type (dry pet food, wet pet food, veterinary diets, treats/snacks, and organic products), ingredient type (animal-derived, plant-derived, cereals and cereal derivatives, and other ingredient types), sales channel (specialized pet shops, internet sales, hypermarkets, and other sales channels), pricing type (economic segment, premium segment, and super-premium segment), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

 

Key Market Trends

 

Rising Trend of Pet Humanization

 

The shift in pet ‘ownership’ to ‘parenting’ has been a very crucial and defining trend in the pet food market, more so in the developed countries. Over a third of the households in the developed countries own a pet. Traditionally, pet owners fed their pet the leftovers and scraps from family meals. However, consumers are now becoming aware about that pet food and home-made food consist of separate nutritional elements, and that pets need to be fed a diverse range of food, as part of an adequate diet.

 

Buyers are looking for products, which are locally grown, or natural, or have digestive benefits. Hence, it is not a surprise that the sales of premium and specialized pet foods are higher than the sales of mid-priced products. Additionally, the pet humanization trend led to an increase in health consciousness and has generated demand for pet food free of sugars, grains, dyes, and other chemical additives.

 

North America Dominates the Pet Food Market

 

Increasing pet humanization and pet ownership, the emergence of private label store brands, and growing urbanization are some of the major driving forces propelling the growth of the North American pet food market. The market is driven by heavy influences from human nutrition, which is driving research to better and safer food for pets that have high nutritional and dietary benefits. Additionally, locally-sourced products and ethically-sourced products are propelling the market, due to the small manufacturers extending their presence in the domestic market.

 

According to the 2017-2018, National Pet Owners Survey, conducted by the American Pet Products Association (APPA), 68% of the US households (about 85 million families) own a pet. The expenditure on pets in the country increased from 41.2% in 2007 to 69.4% in 2017.

 

Competitive Landscape

 

Although, in 2016, the top players contributed around 45%-50% share of the total market, the pet food market is fragmented. However, a series of major deals among big players, like J. M. Smucker Company, Pamplona Capital Management, Spectrum Brands Holdings, and Nestle Purina Petcare, concluded recently, led to gradual consolidation in the market studied.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitutes
4.4.5 Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Animal Type
5.1.1 Dogs
5.1.2 Cats
5.1.3 Birds
5.1.4 Other Animal Types
5.2 Product Type
5.2.1 Dry Pet Foods
5.2.2 Wet Pet Foods
5.2.3 Veterinary Diets
5.2.4 Treats/Snacks
5.2.5 Organic Products
5.3 Ingredient Type
5.3.1 Animal-derived
5.3.2 Plant-derived
5.3.3 Cereals and Cereal Derivatives
5.3.4 Other Ingredient Types
5.4 Sales Channel
5.4.1 Specialized Pet Shops
5.4.2 Internet Sales
5.4.3 Hypermarkets
5.4.4 Other Sales Channels
5.5 Pricing Type
5.5.1 Economy Segment
5.5.2 Premium Segment
5.5.3 Super-premium Segment
5.6 Geography
5.6.1 North America
5.6.1.1 US
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.1.4 Rest of North America
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 UK
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Rest of Asia-Pacific
5.6.4 South America
5.6.4.1 Brazil
5.6.4.2 Argentina
5.6.4.3 Rest of South America
5.6.5 Middle East and Africa
5.6.5.1 South Africa
5.6.5.2 Rest of Middle East and Africa

6 COMPETITIVE LANDSCAPE
6.1 Most Adopted Strategies
6.2 Market Share Analysis
6.3 Company Profiles
6.3.1 Mars Inc.
6.3.2 Nestle Purina Petcare
6.3.3 Nutriara Alimentos Ltda
6.3.4 InVivo NSA
6.3.5 Yamahisa Pet Care
6.3.6 J.M.Sucker (Big Heart)
6.3.7 Wellpet
6.3.8 Blue Buffalo
6.3.9 Diamond Pet Foods

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

Animal Type
Dogs
Cats
Birds
Other Animal Types

Product Type
Dry Pet Foods
Wet Pet Foods
Veterinary Diets
Treats/Snacks
Organic Products
Ingredient Type
Animal-derived
Plant-derived
Cereals and Cereal Derivatives
Other Ingredient Types

Sales Channel
Specialized Pet Shops
Internet Sales
Hypermarkets
Other Sales Channels

Pricing Type
Economy Segment
Premium Segment
Super-premium Segment

Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
South America
Brazil
Argentina
Rest of South America
Middle East and Africa
South Africa
Rest of Middle East and Africa

 

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Ophthalmic Drugs Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
114 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 114 pages
  • Published: 23-07-2019

Market Overview

 

The major factors attributed to the growth of the ophthalmic drugs market include the increasing incidence and prevalence of eye-related disorders, rising R&D activities pertaining to the development of novel drugs, and increasing focus on developing combination therapies.

 

The increasing prevalence of eye diseases is increasing the demand for ophthalmic drugs, globally. In many developed and developing countries, eye conditions have emerged as potential threats to the status of sight of their populations. The increase in the prevalence of diabetes in various countries has caused diabetic retinopathy to be added to the priority list. Glaucoma, an eye disease known for centuries, remains on the public health agenda due to difficulties in its early diagnosis and frequent necessity of life-long treatment. According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had a mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind. Globally, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and the majority of people with vision impairment are over the age of 50 years. According to the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes. More than 80% of the vision impairments are curable or preventable, which means that these drugs are required for the management of the diseases. Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.

 

Scope of the Report

 

As per the scope of the report, ophthalmic drugs are the drugs used for treating glaucoma, cataracts, diabetic retinopathy, and other ophthalmic disorders. An increasing prevalence of eye disorders and increasing R&D on the development of novel drugs are the major factors driving growth in the global ophthalmic drugs market. The market is segmented by drug class, product type, and geography.

 

Key Market Trends

 

The Dry Eye Segment under Drug Class is Expected to Account for the Largest Market Share during the Forecast Period

 

Dry eye disease (DED) is a multi-factorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to aging, and hence, it remains an under-researched condition in the low- and middle-income countries. The prevalence of DED can be as high as 30% of the total population. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the aging population and the adoption of modern lifestyle. Dry eye disease is a common ocular disorder in the elderly and a frequent cause of eye care visits among this age group. The total annual cost of dry eye drug to the US economy can be more than USD 55 billion. Thus, the development of new drug treatments for dry eye is essential for both the dry eye patients and the ophthalmic industry. Many drugs are in the pipeline for dry eye diseases. The increasing prevalence of DED, approval of drugs for its treatment, and government initiatives to eradicate it are the main factors spurring the growth of the market studied.

 

The Asia-Pacific Segment is Expected to Account for the Fastest Growth Rate

 

The ophthalmic drugs market is expanding and growing, globally. The market has been witnessing an especially exponential growth in the Asia-Pacific region. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the Clinical and Experimental Vision and Eye Research, India, 2018. Increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth. According to the National Health Policy (NHP), in India, glaucoma is the leading cause of irreversible blindness with at least 12 million people have affected and nearly 1.2 million people having blinded from the disease. More than 90% of the cases of glaucoma remain undiagnosed in the country.

 

Moreover, the prevalence of glaucoma increases with age. Thus, the rising prevalence of glaucoma and an increase in healthcare expenditure are spurring the growth of the ophthalmic drugs market in India. Furthermore, the country’s government is also playing an important role, since the cost of glaucoma treatment in India is one of the lowest in the world.

 

Competitive Landscape

 

The market studied is composed of a combination of both small and large firms. Most of the big companies are focusing on research and development to bring innovative products to the market. Some of the major players in the ophthalmic drugs market are Aerie Pharmaceuticals Inc., Allergan, Bausch Health, Bayer AG, F. Hoffmann-La Roche Ltd, Hoya Corporation, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders

4.2.2 Rising R&D Pertaining to the Development of Novel Drugs

4.2.3 Increasing Focus on Developing Combination Therapies

4.3 Market Restraints

4.3.1 Loss of Patent Protection for Popular Drugs

4.3.2 Lack of Health Insurance in the Developing Countries

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Drug Class

5.1.1 Anti-glaucoma Drug

5.1.2 Dry eye Drug

5.1.3 Ophthalmic Anti-allergy/Inflammatory

5.1.4 Retinal Drug

5.1.5 Anti-infective Drugs

5.1.6 Other Drugs

5.2 By Product Type

5.2.1 OTC Drug

5.2.2 Prescription Drug

5.3 Geography

5.3.1 North America

5.3.1.1 US

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 UK

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Aerie Pharmaceuticals Inc.

6.1.2 Allergan

6.1.3 Bausch Health Companies Inc.

6.1.4 Bayer AG

6.1.5 F. Hoffmann-La Roche Ltd

6.1.6 Hoya Corporation

6.1.7 Novartis AG

6.1.8 Pfizer Inc.

6.1.9 Regeneron Pharmaceuticals Inc.

6.1.10 Santen Pharmaceutical Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Drug Class

Anti-glaucoma Drug

Dry eye Drug

Ophthalmic Anti-allergy/Inflammatory

Retinal Drug

Anti-infective Drugs

Other Drugs

 

By Product Type

OTC Drug

Prescription Drug

 

Geography

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Oligonucleotide Synthesis Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
115 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 115 pages
  • Published: 23-07-2019

Market Overview

 

The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

 

The usage of synthetic oligonucleotides has been increasing rapidly over the past decade, owing to several benefits offered by molecular diagnostics and growing clinical applications. The nucleic acid application techniques are the reference methods and are very useful for carrying out the molecular diagnosis in several diseases, like for the detection of infectious diseases, such as hepatitis.

 

Synthetic oligonucleotides also have significant clinical applications, primarily for the detection of autoimmune antibodies. There have been consistent developments in synthetic biology over the past few years, where synthetic oligonucleotides were used to develop assays for the detection of anti-double-stranded DNAs. Thus, all these factors are responsible for the growth of the oligonucleotide synthesis market.

 

In addition, there are also other major factors influencing the market for oligonucleotide synthesis. This includes the increasing advancement in the field of healthcare, increasing demand for innovation in the field of life science and medical academics, increasing investment by the government for the development of genomic technologies, and the increasing demand for oligonucleotide synthesis technologies by the public and private research firms.

 

Scope of the Report

 

As per the scope of the report, oligonucleotides are short fragments of nucleic acids that are synthesized using genetic engineering and enzyme chemistry. These are mostly used in laboratories in applications, such as therapeutic, diagnostics, as well as academic and industrial. These are used from initial research and screening through to target validation and drug production. Nowadays, subsequent improvements in oligonucleotide synthesis, amplification, and automation have completely revolutionized biological research. It is also possible to do the customizations and get the required sequence online easily and at the required time. These services vary greatly by the cost of per base pair, error rates, lengths, throughput, etc.

 

Key Market Trends

 

Academic Research Institutes are the Largest Segment Under End User that is Expected to Grow in the Forecast Period

 

The government and private entities are found investing in the development of academic and research infrastructure in the emerging economies. This factor is positively boosting the oligonucleotide adoption in academic research institutes. There is an increase in the genomic research projects conducted by academic research institutes that have enabled the segment to account for the dominant share in the market.

 

North America is the Largest Growing Segment and is Expected to Follow the Same Trend Over the Forecast Period

 

North America dominates the market due to the presence of better health care infrastructure and increasing usage of oligonucleotides by pharmaceutical companies of the region.  Furthermore, the strong foothold of North America in genomics, proteomics, oncology, diagnostic screening, and drug discovery has significantly contributed to maintaining its large share.

 

Competitive Landscape

 

The companies are seen adopting various strategies adopted by the competitors that include the acquisition of players in emerging markets, distribution partnerships, and collaboration for the development of novel technologies. The companies operating in the oligonucleotide synthesis industry are also expanding and developing their product portfolio that helps to drive the overall market.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies

4.2.2 The Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications

4.3 Market Restraints

4.3.1 Price Erosion of Synthesized Oligonucleotides

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product Type

5.1.1 By Synthesized Oligonucleotide Product

5.1.1.1 Primers

5.1.1.2 Probes

5.1.1.3 Large-scale Synthesis Oligonucleotides

5.1.1.4 Intermediate-scale Synthesis Oligonucleotides

5.1.1.5 Other Synthesized Oligonucleotide Product Types

5.1.2 By Reagents

5.1.3 By Equipment

5.2 By Application

5.2.1 By Research

5.2.1.1 PCR

5.2.1.1.1 QPCR

5.2.1.1.2 Sequencing

5.2.1.1.3 Gene Synthesis

5.2.1.1.4 Other Research Application

5.2.2 By Diagnostics

5.2.3 By Therapeutics

5.2.3.1 RNAi

5.2.3.2 Nucleic Acid Aptamers

5.2.3.3 DNA/Antisense Oligonucleotides

5.2.3.4 Other Therapeutics

5.3 By End User

5.3.1 Academic Research Institutes

5.3.2 Pharmaceutical and Biotechnology Companies

5.3.3 Diagnostic Laboratories

5.4 Geography

5.4.1 North America

5.4.1.1 US

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 UK

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East & Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East & Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies

6.1.2 Thermo Fisher Scientific

6.1.3 Merck KGaA

6.1.4 Bio-Synthesis Inc.

6.1.5 Eurofins Genomics

6.1.6 Eurogentec

6.1.7 GE Healthcare

6.1.8 GenScript

6.1.9 Integrated DNA Technologies Inc.

6.1.10 LGC Biosearch Technologies

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Product Type

By Synthesized Oligonucleotide Product

Primers

Probes

Large-scale Synthesis Oligonucleotides

Intermediate-scale Synthesis Oligonucleotides

Other Synthesized Oligonucleotide Product Types

By Reagents

By Equipment

 

By Application

By Research

PCR

QPCR

Sequencing

Gene Synthesis

Other Research Application

By Diagnostics

By Therapeutics

RNAi

Nucleic Acid Aptamers

DNA/Antisense Oligonucleotides

Other Therapeutics

 

By End User

Academic Research Institutes

Pharmaceutical and Biotechnology Companies

Diagnostic Laboratories

 

Geography

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type